Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing ...

Sometimes big breakthroughs in science come from very small changes, curiosity, and more than a little luck. A new study from ...

Focusing on pharmacokinetic and pharmacodynamic mechanisms, Dr Erin C Berthold discusses the interactions between botanical ...

The Vitiligo market presents opportunities through 18+ companies developing 20+ pipeline drugs, with a focus on novel approaches. Key phases include Phase III (Afamelanotide), Phase II (VYN201), and ...

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, ...

Membrane depolarization promotes extracellular signal-regulated kinase activation and cell proliferation via phosphatidylserine dynamics.

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Losing weight is one of the most common goals among adults worldwide. For some, it’s about improving health and longevity.